Benefit assessment in Germany: implications for price discounts

Health Economics Review

Table 8 Summary of the multivariate regression

Model Summary^a
R	R²		R² corr		SE
0.404^a	0.163		0.076		0.1262671
ANOVA^a
	SS	df	MS	F	p-value
Regression	0.540	18	0.030	1.882	0.020^*
Residual	2.774	174	0.016	–	–
Total	3.314	192	–	–	–
Coefficients^a
Predictors (X)		Beta	SE	Coeff (β)	p-value
(constant)		0.228	0.021		0.000
Major benefit		−0.102	0.135	−0.056	0.451
Considerable benefit		−0.033	0.029	−0.091	0.249
Minor benefit		−0.029	0.024	−0.094	0.228
Non-quantifiable benefit		–0.060	0.031	–0.147	0.055
Less benefit		–0.138	0.128	–0.076	0.282
Diseases of the digestive system		0.061	0.055	0.080	0.270
Diseases of the genitourinary system		–0.002	0.093	–0.001	0.984
Endocrine, nutritional and metabolic diseases		–0.017	0.032	–0.042	0.608
Other		0.010	0.051	0.016	0.839
Diseases of the nervous system		0.156	0.047	0.252	0.001**
Diseases of the musculoskeletal system and connective tissue		0.199	0.129	0.109	0.124
Certain infectious and parasitic diseases		0.013	0.025	0.043	0.604
Diseases of the circulatory system		0.043	0.038	0.085	0.264
Diseases of the skin and subcutaneous tissue		0.199	0.128	0.109	0.122
Diseases of the blood and blood-forming organs		0.017	0.092	0.013	0.856
Diseases of the eye and adnexa		–0.029	0.052	–0.041	0.575
Diseases of the respiratory system		–0.086	0.046	–0.138	0.064
Mental and behavioural disorders		0.028	0.092	0.022	0.757

Predictors “Neoplasms” and “No additional benefit” automatically excluded from the model
Abbreviations: Beta standardized coefficient; df degrees of freedom; MS mean squares (SS/dfs); F F statistic; R correlation coefficient; R ² coefficient of determination; R ² corr coefficient of determination corrected; SE standard error; SS sums of squares
** Significant at the 0.01 level
* Significant at the 0.05 level
^a Dependent Variable (Y): price change (discount)

ISSN: 2191-1991